Compare SUPV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPV | PHAT |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.4M | 759.7M |
| IPO Year | 2015 | 2019 |
| Metric | SUPV | PHAT |
|---|---|---|
| Price | $8.69 | $9.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.00 | ★ $19.83 |
| AVG Volume (30 Days) | 662.2K | ★ 1.2M |
| Earning Date | 05-26-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $86.20 | $93.04 |
| Revenue Next Year | $25.12 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $4.54 | $8.21 |
| 52 Week High | $13.55 | $18.31 |
| Indicator | SUPV | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 45.61 |
| Support Level | $7.70 | $8.46 |
| Resistance Level | $8.92 | $9.75 |
| Average True Range (ATR) | 0.44 | 0.48 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 77.27 | 49.44 |
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.